Novartis’ wet AMD drug hits PhII targets

Mid-stage data assessing Novartis’ eye drug RTH258 indicates that it could be an effective option for treating wet age-related macular degeneration, with the added bonus of less frequent dosing than Regeneron/Bayer’s Eylea (aflibercept).

The swiss drug has released Phase II data showing that its experimental drug – a novel, single-chain antibody fragment formerly known as ESBA1008 – hit targets in demonstrating “promising visual acuity gains” that were non-inferior to Eylea, “with numerically greater reduction and rapid improvement in abnormal retinal fluid”.

Patients treated every three months with RTH258 also experienced a prolonged duration-of-action, potentially leading to a reduced treatment burden, Novartis said. Elyea is normally administered every four weeks.

 Novartis eye unit Alcon is now running a Phase III study pitting the efficacy and safety of RTH258 against Eylea in wet AMD patients, which is expected to enroll around 1,700 patients in more than 50 countries worldwide.


Read more at:
Follow us: @PharmaTimes on Twitter

Leave a Reply